The restatement confirms systemic revenue recognition failures and material control weaknesses. Though FY2025 revenue inched up 0.8%, operating income ex-impairments fell ~18% YoY, costs rose, and the $750M buyback consumed cash. With a Nasdaq deficiency notice, the Oct 2025 restructuring, and a class-action lawsuit pending, this is a profoundly negative signal for ICON's accounting credibility and near-term equity performance. Monitor the Q2 2026 6-K amendment for restated quarterly data and the SEC investigation outcome.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 28 $136.80entry
- T+1 · 6mo ago −0.53%α −0.77% · $136.07
- T+5 · 6mo ago +11.70%α +11.38% · $152.80
- T+20 · 5mo ago +24.17%α +27.31% · $169.86
- T+60 · 3mo ago +25.90%α +24.16% · $172.23
Price Chart
How similar events traded
Executive Summary
ICON plc filed its FY2025 20-F, which restates FY2023 and FY2024 financials due to an Audit Committee investigation that found improper revenue recognition and related control failures. Key corrections include a $92.7M revenue overstatement for FY2024 and a $65.3M overstatement for FY2023. Management disclosed material weaknesses in internal controls over financial reporting, and the company recorded a $364.2M goodwill impairment (Data Solutions) and a $101M impairment of other non-financial assets. The filing also notes the disposal of Symphony Health Solutions on May 8, 2026, and a Nasdaq deficiency notice (from the delayed 20-F) received one day prior.
Key Facts
- FY2025 revenue: $8,251M vs FY2024 restated $8,189M (0.8% increase).
- FY2025 GAAP net income: $229M vs FY2024 restated $739M (-69%).
- FY2025 GAAP EPS diluted: $2.90 vs FY2024 restated $8.90.
- Goodwill impairment charge: $364.2M (Data Solutions unit).
- Impairment of non-financial assets: $101M.
- Revenue restated: FY2024 down $92.7M, FY2023 down $65.3M (improper revenue recognition).
- Net income restated: FY2024 down $52.3M, FY2023 down $58.1M.
- Material weaknesses disclosed in internal controls (tone at the top, revenue recognition).
- FY2025 operating income: $442.8M (5.4% margin) vs FY2024 restated $1,032.4M (12.6% margin).
- Share buyback in FY2025: $750M (4,504,330 shares at avg. $166.51).
- Debt at Dec 31, 2025: $3,402.4M net (73% fixed rate).
- Nasdaq deficiency notice received May 26, 2026 due to late 20-F filing.
- Symphony Health Solutions disposed May 8, 2026 for HealthVerity equity and $37.5M cash.
- $500M Bridge Secured Credit Facility entered April 27, 2026 to refinance 2026 Notes.
- Unaudited Obligor Group revenue FY2025: $7,458M; net income: $697M.
Financial Impact
Revenue overstated by ~$158M cumulatively over FY2023-2024. FY2025 GAAP operating margin collapsed to 5.4% from 12.6% due to $465M in impairment charges. The delayed filing triggered a Nasdaq deficiency notice.
Risk Factors
- Potential SEC enforcement action and shareholder lawsuits beyond the consolidated class action.
- Nasdaq delisting if 20-F compliance is not restored within the cure period.
- Further credit rating downgrade (Moody's already shifted outlook to stable from positive in Feb 2026).
- Additional impairment charges if Data Solutions revenue continues to decline.
- Execution risk on the remediation plan for material weaknesses; further restatements possible.
- $500M 2026 Notes maturity in July 2026, bridge facility provides liquidity but adds leverage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001628280-26-038487 |
| Exhibit: exhibit212.htm | 0001628280-26-038487 |
Track record
25 reports on ICLR
3 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +33.70% at T+60 after the Aug 6, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $190.43 Now $191.40 +0.51% settles Nov 17
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $194.65 to $191.40 Now $191.40 −1.67% ▼ −1.67% +0.24% vs SPY
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $204.63 to $199.70 Now $191.40 −6.47% ▼ −2.41% −3.73% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $201.65 to $204.74 Now $191.40 −5.08% ▲ +1.53% +1.22% vs SPY
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $203.11 to $201.65 Now $191.40 −5.77% ▼ −0.72% +3.69% vs SPY
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $203.11 to $201.65 Now $191.40 −5.77% ▼ −0.72% +3.69% vs SPY
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $203.77 to $203.11 Now $191.40 −6.07% ▼ −0.32% −1.98% vs SPY
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $203.77 to $203.11 Now $191.40 −6.07% ▼ −0.32% −1.98% vs SPY
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $203.77 to $203.11 Now $191.40 −6.07% ▼ −0.32% −1.98% vs SPY
- Oct 27, 202620d ago 6-K Bearish 5/10 Entry $214.16 to $215.48 Now $191.40 +10.63% ▼ −0.62% −1.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers